Post-Traumatic Stress Disorder Treatment: New Product Launches to Improve Mental Health

There has been a significant surge in the demand for post-traumatic stress disorder treatments due to the increase in the number of people having exposure to traumatic events in their lives such as sexual assault, warfare, traffic collisions, child abuse, or other threats to a person's life. Thus, increase in the burden of post-traumatic stress disorder worldwide, a rise in the number of clinical trials pertaining to post-traumatic stress disorder treatment, as well an increase in R&D activities for the introduction of novel therapies and drugs are expected to drive the growth of the global post-traumatic stress disorder treatment market.

• New Product to Promote a Sense of Psychological Safety

Numerous players of the market in various countries are launching innovative post-traumatic stress disorder treatment products to effectively cater to needs of people. For instance, ATAI Life Sciences, a global biotech developing psychedelic and non-psychedelic compounds for various mental health indications, announced the launch of its subsidiary called EmpathBio to treat post-traumatic stress disorder with novel MDMA (3,4-methylenedioxy-methamphetamine ) product.

EmpathBio is a wholly-owned subsidiary developing derivatives of (MDMA) used for the treatment of post-traumatic stress disorder (PTSD) and other indications. MDMA's entactogenic effects typically last approximately six hours, and are hypothesized to promote a sense of psychological safety that allows patients to more effectively address their individual traumas during psychotherapy than before. EmpathBio develops the derivatives of MDMA, which are known to have similar effects.

Glenn Short, the Chief Executive Officer of EmpathBio, mentioned in a statement that MDMA-assisted psychotherapy holds great promise for the treatment of PTSD. On the other hand, refinement of MDMA's entactogenic pharmacology could provide for a greater therapeutic index. He further adds that the company aims to ensure that entactogen-assisted psychotherapy is available and effective to all people living with PTSD.

• New Product to Help Treat Various Mental Issues

The trend of launching innovative post-traumatic stress disorder treatment products by prominent players of the market continues to gain massive momentum in the healthcare industry. For instance, Jazz Pharmaceuticals, plc, a dominant global biopharmaceutical company dedicated to bringing life-changing medicines to people, announced that its first patient has been enrolled in a Phase 2 clinical trial evaluating the safety and efficacy of JZP150, an investigational first-in-class small molecule for the treatment of adults with post-traumatic stress disorder (PTSD).

JZP150 is a highly selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH), which is specifically designed to not only address the underlying cause of PTSD but also treat patients suffering from anxiety, insomnia, and nightmares. JZP150 was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for PTSD based on the serious nature of the disorder. This was mainly done to facilitate the development of new effective medicines. In addition, there was a need to expedite the review of medicines that treat serious conditions and have the potential to address unmet medical needs.

Rob Iannone, Managing Director, M.S.C.E., the Executive Vice President for research and development and Chief Medical Officer of Jazz Pharmaceuticals, mentioned in a statement that FDA's Fast Track designation of JZP150 is a remarkable recognition of the serious, ongoing, and unmet medical needs of PTSD patients. The potential benefits of JZP150's novel mechanism efficiently help treat this debilitating disorder.  

Thus, persistent product launches and increased healthcare expenditure among people are expected to create ample opportunities for the market.

Related Post